戈利木单抗（抗TNF单克隆抗体）：我们目前的进展情况。
Golimumab (anti-TNF monoclonal antibody): where we stand today.
作者信息
Melo Ana Teresa, Campanilho-Marques Raquel, Fonseca João Eurico
机构信息
Rheumatology Department, Hospital De Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal.
Rheumatology Research Unit, Instituto De Medicina Molecular João Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa, Lisbon, Portugal.
出版信息
Hum Vaccin Immunother. 2021 Jun 3;17(6):1586-1598. doi: 10.1080/21645515.2020.1836919. Epub 2020 Dec 28.
Abstract
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inflammation. It is approved for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Nonradiographic axial Spondyloarthritis, Juvenile Idiopathic Arthritis, and Ulcerative Colitis. Clinical trials are also being conducted in other conditions. This review charts the clinical development of golimumab and outlines the data that support its potential use across several Immune-mediated inflammatory diseases.
摘要
肿瘤坏死因子（TNF）是一种促炎细胞因子，其过度表达与几种慢性免疫介导的炎症性疾病的病理生理学有关。生物疗法，如TNF抑制剂，一直在彻底改变这些疾病的病程。戈利木单抗是一种转基因抗TNF单克隆抗体，主要通过靶向和中和TNF发挥作用，从而预防炎症。它被批准用于治疗类风湿性关节炎、银屑病关节炎、强直性脊柱炎、非放射性轴性脊柱关节炎、幼年特发性关节炎和溃疡性结肠炎。目前也正在对其他病症进行临床试验。本综述阐述了戈利木单抗的临床开发情况，并概述了支持其在多种免疫介导的炎症性疾病中潜在应用的数据。
相似文献
1
Golimumab (anti-TNF monoclonal antibody): where we stand today.戈利木单抗（抗TNF单克隆抗体）：我们目前的进展情况。
Hum Vaccin Immunother. 2021 Jun 3;17(6):1586-1598. doi: 10.1080/21645515.2020.1836919. Epub 2020 Dec 28.
2
Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗：一种用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎的新型抗肿瘤坏死因子-α人单克隆抗体。
Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434.
3
Golimumab for the treatment of axial spondyloarthritis.戈利木单抗治疗中轴型脊柱关节炎。
Expert Rev Clin Immunol. 2016;12(1):9-18. doi: 10.1586/1744666X.2016.1106941. Epub 2015 Nov 2.
4
Golimumab for treatment of axial spondyloarthritis.戈利木单抗治疗中轴型脊柱关节炎。
Immunotherapy. 2016 Feb;8(2):107-15. doi: 10.2217/imt.15.112. Epub 2016 Jan 22.
5
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.戈利木单抗：用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎。
BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005.
6
Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations.戈利木单抗用于多关节型幼年特发性关节炎和银屑病关节炎：药理学及临床考量
Life (Basel). 2023 Jul 21;13(7):1601. doi: 10.3390/life13071601.
7
Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗：一种新型抗 TNF-α 药物，用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎。
Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49.
8
Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.戈利木单抗：一种用于治疗类风湿关节炎、强直性脊柱炎和银屑病关节炎的新型人抗肿瘤坏死因子-α单克隆抗体。
Core Evid. 2010 Jun 15;4:159-70. doi: 10.2147/ce.s6000.
9
Golimumab - a new tool in the armoury against inflammatory arthritis.戈利木单抗——对抗炎症性关节炎的新武器。
Ann Med. 2011 Mar;43(2):133-41. doi: 10.3109/07853890.2010.549148. Epub 2011 Jan 18.
10
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study.戈利木单抗作为一种二线生物药物在脊柱关节炎患者中的疗效和持久性：一项回顾性研究。
Medicine (Baltimore). 2021 Apr 2;100(13):e25223. doi: 10.1097/MD.0000000000025223.
引用本文的文献
1
Identification of potential hub genes and drugs in septic kidney injury: a bioinformatic analysis with preliminary experimental validation.脓毒症性肾损伤中潜在枢纽基因和药物的鉴定：一项具有初步实验验证的生物信息学分析
Front Med (Lausanne). 2025 Mar 17;12:1502189. doi: 10.3389/fmed.2025.1502189. eCollection 2025.
2
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.阿巴西普、戈利木单抗和托珠单抗作为当前治疗中具有不同作用机制的选定生物原研改善病情抗风湿药。
J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107.
3
Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era.一名银屑病关节炎患者的脾脏炎性假瘤：COVID-19 时代的诊断挑战
Cureus. 2024 Nov 6;16(11):e73121. doi: 10.7759/cureus.73121. eCollection 2024 Nov.
4
Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.戈利木单抗和聚乙二醇化赛妥珠单抗治疗化脓性汗腺炎：文献综述与未来展望
Ther Adv Chronic Dis. 2024 May 31;15:20406223241257342. doi: 10.1177/20406223241257342. eCollection 2024.
5
Early identification of golimumab-treated patients with higher likelihood of long-term retention.早期识别更有可能长期保留的戈利木单抗治疗患者。
Front Immunol. 2024 Apr 5;15:1359571. doi: 10.3389/fimmu.2024.1359571. eCollection 2024.
6
Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study.患者对治疗风湿性疾病的戈利木单抗和依那西普治疗的自我报告体验和满意度：一项队列研究。
Medicine (Baltimore). 2024 Feb 23;103(8):e36982. doi: 10.1097/MD.0000000000036982.
7
Research progress of targeted therapy regulating Th17/Treg balance in bone immune diseases.靶向治疗调节骨免疫疾病中 Th17/Treg 平衡的研究进展。
Front Immunol. 2024 Jan 30;15:1333993. doi: 10.3389/fimmu.2024.1333993. eCollection 2024.
8
The role of inflammation in autoimmune disease: a therapeutic target.炎症在自身免疫性疾病中的作用：一个治疗靶点。
Front Immunol. 2023 Oct 4;14:1267091. doi: 10.3389/fimmu.2023.1267091. eCollection 2023.
9
Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations.戈利木单抗用于多关节型幼年特发性关节炎和银屑病关节炎：药理学及临床考量
Life (Basel). 2023 Jul 21;13(7):1601. doi: 10.3390/life13071601.
10
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments.将纳米技术与单克隆抗体药物相结合治疗类风湿性关节炎。
J Nanobiotechnology. 2023 Mar 25;21(1):105. doi: 10.1186/s12951-023-01857-8.
本文引用的文献
1
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.GO-DACT 研究：戈利木单抗联合甲氨蝶呤（MTX）与安慰剂联合 MTX 治疗初治银屑病关节炎患者的 3b 期随机、双盲、安慰剂对照试验，以改善 DACTylitis。
Ann Rheum Dis. 2020 Apr;79(4):490-498. doi: 10.1136/annrheumdis-2019-216500.
2
Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond.结核病与生物疗法：抗 TNF-α 及其他。
Clin Chest Med. 2019 Dec;40(4):721-739. doi: 10.1016/j.ccm.2019.07.003.
3
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis.培塞利珠单抗和戈利木单抗治疗非感染性葡萄膜炎的疗效和安全性。
Clin Exp Rheumatol. 2019 Jul-Aug;37(4):680-683. Epub 2019 Apr 3.
4
Golimumab for Rheumatoid Arthritis.戈利木单抗治疗类风湿关节炎
J Clin Med. 2019 Mar 20;8(3):387. doi: 10.3390/jcm8030387.
5
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.戈利木单抗的免疫原性及其在溃疡性结肠炎患者中的临床相关性。
Inflamm Bowel Dis. 2019 Aug 20;25(9):1532-1540. doi: 10.1093/ibd/izz003.
6
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗的免疫原性及其在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的临床相关性。
Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309.
7
Golimumab in inflammatory bowel diseases: present and future scenarios.戈利木单抗在炎症性肠病中的应用：现状与未来展望
Clin J Gastroenterol. 2019 Feb;12(1):1-9. doi: 10.1007/s12328-018-0906-9. Epub 2018 Sep 11.
8
The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.戈利木单抗作为难治性克罗恩病患者三线或四线抗TNF治疗的疗效和安全性：病例系列
Inflamm Intest Dis. 2017 Nov;2(2):131-138. doi: 10.1159/000481400. Epub 2017 Oct 19.
9
A New Venue of TNF Targeting.TNF 靶向治疗的新途径。
Int J Mol Sci. 2018 May 11;19(5):1442. doi: 10.3390/ijms19051442.
10
The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review.TNF 抑制剂在银屑病女性妊娠期间的使用和安全性：综述。
Int J Mol Sci. 2018 May 3;19(5):1349. doi: 10.3390/ijms19051349.
Zotero 插件